



**Interplast**<sup>®</sup>

Repairing bodies & rebuilding lives  
in the Asia Pacific region



Interplast Australia & New Zealand

# ANNUAL REPORT

## 2021 - 2022

# ABOUT US

Interplast Australia & New Zealand (Interplast) provides life-changing surgery and health professional training in 17 countries across the Asia Pacific region, made possible by our volunteer plastic and reconstructive surgeons, anaesthetists, nurses and allied health professionals.

We do this in partnership with local organisations, including hospitals, universities and local NGOs. Our purpose is to 'repair bodies and rebuild lives' and we do this by providing surgical services to those who could not otherwise afford or access these, and through building the capacity of local medical systems through our training and mentoring programs.

Interplast is an accredited non-government organisation with the Department of Foreign Affairs and Trade (DFAT), registered by the Australian Charities and Not For Profit Commission (ACNC) and is a signatory to the Australian Council for International Development (ACFID) Code of Conduct.

Interplast was initially established in 1983 by the Royal Australasian College of Surgeons in partnership with Rotary. Interplast is a company limited by guarantee.

## Our vision

Life-changing surgical & related healthcare, for all.

## Our mission

Enhancing quality of life through positive surgical and health outcomes

## Our values

In all that we do, we will demonstrate our values of integrity, respect, and collaboration.

## Our guiding principles

Interplast seeks to ensure that surgery and related health services across the Asia Pacific region should be:

- Effective
- Accessible
- Equitable
- Sustainable
- Patient-centred.



Interplast Australia & New Zealand is actively supported by Rotarians in Clubs and Districts throughout Australia and New Zealand.




Interplast Australia & New Zealand is a member of the Australian Council for International Development (ACFID) and signatory to the ACFID Code of Conduct.



The Royal Australasian College of Surgeons established Interplast with Rotarians and the Fellows remain active supporters.

# PRESIDENT'S REPORT



**Globally, the COVID19 pandemic has strained healthcare systems by creating the devastating imbalance between needs and resources.**

This impact has been felt hardest in developing nations where already strained systems struggle to accommodate the new and ongoing challenges inflicted by the pandemic. As we have done since our beginnings in 1983, Interplast Australia & New Zealand has again prioritised the needs of our partners across the Asia Pacific region and responded to the challenges with innovative solutions.

Although the 2021/22 year again saw our highly skilled surgical and allied health teams remain grounded due to worldwide travel restrictions, our ongoing commitment to developing a sustainable surgical workforce, together with our work to improve clinical settings and to create long-term positive change within health systems has resulted in another positive year of life-changing program delivery. This work has been more important than ever for partners in the Asia Pacific region.

I congratulate everyone involved in the delivery of our innovative programs as we continue to

deliver our important mission. As it has done since the emergence of COVID19, our work evolved again throughout the year, however our commitment to exceptional care has not changed. The achievements highlighted throughout this report are vast, and I encourage every person involved to be rightly proud of the positive impact achieved by Interplast this past year.


The work of Interplast is not undertaken in isolation. As I have written previously, our strength lies in our partnerships. We only work through invitation, and we only work in collaboration with our valued partners. The support we offer is tailored to local need and our work is designed to support local leadership and the championing of local solutions. The past year has again highlighted the importance of these relationships and the strength that comes from this shared approach to positive outcomes. We sincerely hope that the year ahead will allow us to return once again for in-person work alongside our partners.

In celebrating our work, I wish to acknowledge every partner, volunteer, donor, supporter and staff member for your continued belief in our work. It is this belief that leads to action, and in turn the life-changing outcomes achieved by Interplast. Whether involved with the organisation for a short-period or an extended tenure, every individual contributes to the rich mix that makes the organisation one to celebrate. On behalf of the entire Interplast Board, I thank you for your contribution and continued commitment. Together, we are changing lives.

I wish to acknowledge my fellow Directors for their dedication throughout the 2021/22 financial year. As the organisation continued to navigate the challenges of a global pandemic and the shifting trends within the international development sector, they again showed their commitment to good governance and effective stewardship of Interplast. Working effectively with our staff team, the Board embraced every challenge and navigated it with great skill. Interplast is stronger because of their leadership.

This report will be my last as President of Interplast, however I depart the position knowing those who follow do so with great skill and passion for our work. As Interplast looks to the future, and celebrates nearly 40 years of life-changing work, I remain honoured to have served as President and to have helped shape our impact across the Asia Pacific region.

As we reflect on the year that was, and look to the years ahead, do so with great pride.



**Michael McGlynn OAM**  
**President**  
**Interplast Australia & New Zealand**

# CEO'S REPORT



**COVID19 isn't the only health crisis facing the world. Globally, 5 billion people are still without access to safe and effective surgery. We must address that number.**

Once again, the incredible volunteers who make up the bulk of our work remained grounded due to travel restrictions imposed by governments around the world seeking to reduce the transmission of COVID19. Although they could not travel, their impact was enormous.

With a continued focus of delivering exceptional patient care, building a sustainable surgical workforce, strengthening hospitals and clinical settings, and working to create positive systemic change in the countries in which Interplast works, the 2021/22 year was again successful.

#### **Direct Patient Care:**

- 75 patients have directly benefited from Interplast support in the form of surgical services and consultations
- 50 specialist bottles and 60 teats were delivered to Bhutan to aid children with cleft lips and palates

- Interplast developed and delivered a Hand Therapy Kit pilot with the aim of delivering tailored at-home rehabilitation for remote and rural communities
- Over 300 healthcare workers were supported to undertake training in burns prevention and treatment.
- Clinical equipment and supplies were provided to surgical colleagues across the Asia Pacific region who would otherwise be unable to access these items.

#### Workforce Development:

- 1060 clinicians received training via Interplast's live education webinars
- 26 webinars have been delivered by Interplast's volunteer clinicians with participants joining from 35 countries and territories
- Interplast's digital education offering remained popular with over 2,000 views of customised clinical content achieved during the 2021/22 period
- 8 small group mentoring sessions were held in Fiji and Papua New Guinea, with remote training proved by Interplast volunteers
- 2 online symposia were conducted in June on Plastic Surgery Nursing, and Allied Health. The 335 registrants across the two events received 6 hours of engaging educational content and network opportunities
- In partnership with other leading organisations, Interplast has continued to deliver the Essential Pain Management online education module. This has seen approximately 8,000 individuals undertake this world-class training module.

#### Hospital Improvement:

- 14 hospitals across the Asia Pacific region were actively engaged in hospital improvement initiatives delivered by Interplast. A major focus on gender and disability inclusion during 2021/22 has been essential for improving access to life-changing care.

#### System Strengthening:

- Two significant research projects were undertaken, including:
  - A baseline research project focused on the unacceptably high rates of diabetic foot disease in the Pacific Island nations
  - A baseline research project examining the state of plastic and reconstructive surgery in Pacific Island countries

None of the work undertaken by Interplast, either locally or internationally would be possible without an exceptional team of volunteers who give freely of their time and talent. This year, whilst facing their own challenges within the Australian and New Zealand health sector, they have once again delivered exceptional results, and I thank them sincerely for their ongoing support of the organisation.

I also wish to acknowledge Interplast's donors and supporters. Every year, this passionate group of individuals has continued to advocate for, and champion the work of the organisation.

Last but by no means least, let me thank the staff and Board team at Interplast. As I have written previously, they are passionate, dynamic and visionary. Every time they are asked to work differently, work longer and work harder for the benefit of those we support, this group push harder and further.

In presenting this annual report, I congratulate everyone involved with Interplast. When working as one, Interplast is a powerful force changing lives.



**Cameron Glover**  
**Chief Executive Officer**  
**Interplast Australia & New Zealand**



## MEET ANHKBAYAR



At just 14-months old, Mongolian boy Ankhbayar was badly burned on his face by a hot oven. The injuries to his face meant that he was unable to sleep with his eyes closed, and he was suffering great pain.

Following the injuries, he required a great deal of personal care to keep the skin clean, and the skin around the affected eye had healed in a way that prevented young Ankhbayar from closing it.

When severely burnt skin heals, tight scars cause the skin to contract, preventing natural movements and causing pain and deformity. Contracture scars are particularly damaging for children, because as the child grows, the scar will not. Early intervention is crucial for young children and, thankfully, Ankhbayar was fortunate in this regard, the beneficiary of life-changing surgery from the visiting Interplast team.

Children require multiple interventions as they grow to ensure the best outcomes from surgery. That's why capacity building activities and ongoing partnerships between local and Interplast surgeons are so essential.

**As the world begins to open up to a new 'normal' and living alongside COVID19, Interplast volunteers will travel again in 2022/23.**

**It is children like Ankhbayar that makes this travel essential. No child should have to wait for life-changing surgical care.**

# OUR WORK

At Interplast, we focus on four complementary areas of program work: direct patient care, building a sustainable surgical workforce, improving clinical institutions and creating lasting change through enhancing health systems. As in previous years, the impact of COVID-19, and subsequent travel restrictions altered how we worked, but we continue to support our partners through these complementary focus areas.

## Quality and accessible patient care

Interplast believes that every girl and boy, woman and man should be able to access life-changing surgical and related medical care when it is needed.

Recognising that this is not currently possible across the Asia Pacific region, Interplast has continued to provide essential care to those in need.

Traditionally, prior to the emergence of COVID19, our patient care was provided by sending experienced Interplast volunteers to partner countries to deliver surgical and allied health services. With teams unable to travel, the organisation modified its programmatic approach to focus on remote-services designed to benefit individuals experiencing:

- Burns related trauma
- Congenital and acquired disability
- Non-burns related trauma

## Developing a sustainable surgical workforce

Capacity and capability building of the surgical workforce across the Asia Pacific region is of paramount importance.

To ensure individuals requiring care are well supported by specialist medical professionals, Interplast is committed to upskilling surgeons, anaesthetists, nurses and allied health professionals involved in patient care.

During 2021/22, our commitment to building a sustainable workforce focused on longer-term capabilities. Through the provision of digital education, remote mentoring and large-scale

symposia, Interplast has continued to support our medical colleagues throughout the Asia Pacific region.

## Strengthening clinical institutions

The World Health Organisation estimates that 134 million adverse events occur each year in hospitals in low and middle-income countries, contributing to 2.6 million deaths annually as a result of unsafe care.

This past year we have worked closely with partner hospitals to help them improve their practice, including helping with the adoption of policies and practices that support individuals with disabilities.

A large part of this work also focused on ensure healthcare was accessible to women – a group significantly disadvantaged by the lack of universal health coverage.

## Enhancing health systems

It is estimated that there are 143 million additional surgical procedures needed every year to save lives and prevent disability. The need for systemic change to address significant disadvantage is evident.

Our 2021/22 programming involved working with local partners to improve their systems, processes and resources to enhance patient care and health outcomes.

# **SIGNIFICANT ACHIEVEMENTS**





# QUALITY & ACCESSIBLE PATIENT CARE

## Hand Therapy Kit Pilot

How do you support a hand patient who lives too far to travel for rehabilitation services? How do you provide rehabilitation when COVID19 prevents visits to local hospitals and therapy services? Introducing Interplast's Hand Therapy Kit Pilot Program.

Piloted with the aim to enable tailored at-home rehabilitation for remote and rural patients, the kits are a new initiative to support local therapists in our partner countries to improve their patients' treatment.

The kits take a 'symptoms management approach' and give therapists a choice of materials so that they can customise treatment for their patients.

The kits are being piloted in Fiji with 2 therapists who have long-established mentoring relationships with Interplast volunteers, and we estimate they will benefit between 80 and 100 patients.



## Reducing Surgical Barriers



During FY23 the program will be extended to include other countries across the Asia Pacific.

Sometimes access to surgeons, anaesthetists and nurses isn't the only barrier to surgery. Cost can be prohibitive in some countries throughout the Asia Pacific region.

Once again Interplast was able to provide direct funding support to individuals who were unable to access surgical services as a result of financial burdens.

In addition to funding support, Interplast provided remote mentoring and case planning assistance to our overseas colleagues to ensure patient care was continued to the highest of standards.

---

## Providing Life-changing Equipment

Whilst the movement of people overseas proved impossible during the financial year, Interplast was able to deliver much-needed equipment to our partner hospitals.

The specialist cleft bottles and teats delivered to Bhutan will ensure children with cleft lips and palates are able to feed and obtain the nutrients they require.

# WORKFORCE DEVELOPMENT



## 2021/22 –The Year of Our Symposia

The first of its kind for Interplast, the *Plastic Surgery Nursing Symposium* attracted 160 participants in total, with 112 participants from ODA eligible countries, and the remaining from other, non-ODA countries.

The highlight was an interactive discussion on working in partnership, which was demonstrated by the work undertaken for Interplast's Pacific Perioperative Modules, produced in partnership with SPC (the Pacific Community) and the Royal Australasian College of Surgeons.

## Hand in Hand Symposium

Building upon the success of the Nursing Symposium, Interplast delivered an allied health symposium attended by 187 participants. Sessions focused on the barriers facing people with disability in accessing allied health and other clinical services, together with the role of allied health in positive surgical outcomes.

*"It's good to see concerns of nurses in our field for the simple reason that we work closely together in the care of our patients. I actually shared this event to nursing friends and they appreciated it very much. They saw how similar and/or different practice is elsewhere. It is always good to see other experience abroad."*

Nursing Participant

## Women in Clinical Leadership



In conjunction with *Women In Medicine Mongolia*, Interplast hosted two webinar events focused on women in medicine. Focused on the sharing of leadership, insights, and advice amongst female clinicians in the Asia Pacific region, over 70 participants joined for this event.

A further 17 women were invited by invitation to an International Women's Day Clinical Networking event to *#breakthebias*. Together they shared experiences and advice on a range of issues relevant to career progression and participation in surgery in developing countries.

## Our Ongoing Commitment to Education

Building upon the success of the digital clinical offering undertaken in the previous financial year, once again Interplast delivered 26 webinars, attended by 1060 clinicians from across 35 countries and territories.

Previously developed education hosted on the Praxhub platform received an additional 2,000 views by clinicians in developing countries.

# STRENGTHENING CLINICAL SETTINGS

## Gender and Disability Meta Analysis

Women and individuals with a disability are often the most affected by inequality within health settings.

In partnership with the Royal Australasian College of Surgeons, Interplast commissioned The Nossal Institute to conduct an analysis of country-specific data in six Pacific Island nations:

- Fiji
- Kiribati
- Samoa
- Solomon Islands
- Tonga

The findings of the analysis are important for future program design and will lead to comprehensive programs designed to support individuals with a disability, together with women and children.

## GEDI Awareness Training

At the request of our international partners, Interplast together with RACS worked alongside a Pacific-based consultant to develop disability awareness training for clinicians working in the Asia Pacific region.

The training looks at ways to reduce barriers to care, engage with respect and dignity and the creation of care plans for patients experiencing disability.

The training will roll-out across six Pacific Island countries in FY23 and into Asia following the pilot program in the Pacific.

## Mentoring on a Global Scale

As part of Interplast's commitment to building stronger clinical settings, 2021/22

saw the provision of financial support for a Fijian physiotherapist to attend the International Hand Congress in London.

In turn, Akisi will return to Fiji and build the practice of hand therapy amongst her peers.



# CREATING SYSTEMIC CHANGE

## Investigating The State of Surgery

To understand the baseline coverage of surgical care in the Pacific, Interplast engaged the Nossal Institute to undertake a *State of Surgery* research report. The research explored the state of plastic and reconstructive surgery in seven Pacific Island Countries, including:

- Fiji
- Kiribati
- Papua New Guinea
- Vanuatu
- Samoa
- Solomon Islands
- Tonga

The purpose of the reasearch was to explore workforce capacity and the current levels of plastic and reconstructive surgical services.

With the report now received, Interplast will begin to share the report more widely and use the findings to inform future programming design and grant applications.




---

## Understanding the Diabetic Foot

All too often, the late diagnosis and limitations of care in Pacific Island Countries leads to amputation of diabetic limbs. This is a growing burden on the community and one which Interplast has been asked by our partners to support.

Conducted by the University of Adelaide, and in partnership with the Royal Australasian College of Surgeons, the research report highlights:

- Gaps in workforce capacity
- Treatment options
- Burden of disability
- Recommendations for future action

With support of Interplast, and other relevant NGOs, clinicians working in this complex field will receive ongoing training and mentoring to reduce the incidence of Diabetic Foot Disease, and associated complications.

---



# OUR COMMITMENT TO MONITORING, EVALUATION & LEARNING

Interplast places monitoring, evaluation and learning at the centre of all program planning, design and implementation. Our monitoring and evaluation framework guides a whole-of-organisation approach to measuring impact, informing what our programs have achieved, and identifying where improvements can be made, so that resources are targeted towards areas where they have maximum benefit.

The current Interplast Monitoring, Evaluation and Learning Framework was established in 2021 and was designed to help us understand the effectiveness and appropriateness of Interplast's strategy on its intended outcomes, and to capture any unexpected outcomes (both positive and negative). Furthermore, the framework also aims to enable accountability to Interplast stakeholders and allow for the organisation to continuously improve our work and make evidence-based decisions.

The monitoring and evaluation of Interplast's programming, and documenting and embedding lessons learned is overseen by Interplast's Design, Monitoring and Evaluation Committee, which reports directly to the Board of Directors.



Importantly, the framework shaped the continual improvement work done in 2021-2022 in relation to the monitoring and evaluation of programming, including updating and improving the way that we capture and analyse data, and how this data informs our ongoing programming.





# VOLUNTEERS – THE HEART OF INTERPLAST

Without the continuing determination and passion of our valued volunteers, Interplast could not achieve its purpose of repairing bodies and rebuilding lives.

Our surgeons, nurses, anaesthetists, and allied health professionals continue to give of their time and talents to provide essential assistance to their colleagues and patients across the Asia Pacific region.

During 2021/22, Interplast volunteers:

- Continued to be trusted advisors by making themselves available for remote mentoring and support to their international peers
- Offered patients hope and access to life-changing care by reviewing clinical files and providing remote consultations at a time where travel proved impossible
- Delivered hours of on-demand clinical education through the provision of webinars, and training modules
- Assisted in the development of resources, policies and other essential initiatives at the request of our partners.

A number of our volunteers give an additional contribution as Country Coordinators, providing advice and input into Interplast program planning, monitoring and evaluation.

Additionally, many of our volunteers also support Interplast by serving on our Board, committees and working groups providing clinical governance and support.

*“A privilege, an opportunity to give back, to teach, to train and help those who for no fault of their own, are in a significantly less fortunate place. The simple things are often the most undervalued, and all too frequently, the most important.”*

Mark Ashton  
Specialist Plastic & Reconstructive Surgeon

---

*“Extremely rewarding to be given the opportunity to provide education to Nurses that would not otherwise receive this.”*

Carolyn Gear  
Nurse Educator

---

*“It is such a privilege to see that the work I do for Interplast, which seems so small to me - teaching the management of hand and burn injuries, can have such a significant and lasting impact on other lives.”*

Penny McMahon  
Occupational Therapist

---

*“It is great to do something for people with real problems, who have no other alternative and are genuinely grateful.”*

Robert Grace  
Specialist Anaesthetist

---

# PARTNERSHIPS

Interplast could not succeed without the incredible individuals, groups and businesses who, each year, join us in raising funds and promoting the work of our organisation. It's these supporters who make it possible to achieve our purpose of repairing bodies and rebuilding lives in the Asia Pacific region. We thank each and every one of you for the difference that you make.

## Corporate and Philanthropic Partners

Interplast continues to be supported by some of Australia & New Zealand's most respected corporate and philanthropic partners, who demonstrate their ongoing commitment to providing life-changing care across the Asia Pacific region.

In 2021/22 we wish to thank and acknowledge:

- Avant
- Chemtronics Biomedical Engineering
- Device Technologies
- Johnson & Johnson Medical
- Leconfield Wines
- Medical + Optical
- Medtronic
- MicroCloud
- MinterEllison
- The Noel & Carmel O'Brien Family Foundation
- The Orloff Family Charitable Trust
- OPC Health
- Stryker
- Therapist Support Laboratory (TSL)
- Victor Smorgon Charitable Fund
- Australian Hand Therapy Association
- Australian and New Zealand Burn Association
- Australian and New Zealand College of Anaesthetists
- Australian Society of Anaesthetists
- Australasian Society of Aesthetic Plastic Surgeons
- Australian Society of Plastic Surgeons
- Children First Foundation
- Interburns
- Lifebox Foundation
- New Zealand Association of Plastic Surgeons
- New Zealand Society of Anaesthetists
- ReSurge International
- Royal Australasian College of Surgeons
- Rotary Oceania Medical Aid for Children
- Rotary New Zealand World Service Limited
- SPC (The Pacific Community)

In addition to the businesses and foundations listed, we wish to acknowledge the suppliers and individuals with whom we regularly work, many of whom go above and beyond for us. Although there are too many to mention by name, we would like to particularly acknowledge Clinical Imaging, Gippsland Broadband, Left of Boom, PPT Managed Services, Praxhub, Rusty Assets, and Connecting Up. Every one of these suppliers is passionate about working with Interplast to change futures. We cannot thank them enough for their contribution.

## Industry Partners

Interplast Australia & New Zealand is supported by partners who collaborate with and support us in our work providing life-changing surgical and associated health services across the Asia Pacific region. We thank each of the following organisations for your contribution in 2021/22:

- Australasian Foundation for Plastic Surgery

## Australian Government:

Interplast acknowledges the importance of its participation in the Australian Government's Australian NGO Cooperation Program (ANCP). With the support of the Australian Aid Program, and the many NGOs who are a part of it, Interplast is able to continue and broaden its life-changing work.

## CELEBRATING LIFEBOX AUSTRALIA & NEW ZEALAND

Lifebox Australia and New Zealand (Lifebox ANZ) is a partnership between the Lifebox Foundation, Interplast, the Australian and New Zealand College of Anaesthetists (ANZCA), the Australian Society of Anaesthetists and the New Zealand Society of Anaesthetists.

Together, this partnership helps strengthen anaesthesia and surgical safety through the distribution of pulse oximeters and associated training to hospitals across the Asia Pacific region.

Monitoring oxygen levels in the blood is essential for anaesthetised patients during surgical procedures, as the slightest change can lead to organ failure, brain injury and death. Pulse oximeters are a vital tool in low-resource settings that allow healthcare professionals to respond swiftly when a patient requires oxygen support.

These devices also play a critical role in the assessment and treatment of COVID-19 patients, utilising oxygen saturation levels to help determine when medical intervention is required.

In 2021/22, Lifebox ANZ continued to play a significant role in the distribution of pulse oximeters across the Asia Pacific region.



# ROTARY & INTERPLAST – TOGETHER AS ONE

Interplast was established in 1983 as a joint project between Rotary District 980 (now 9800) and the Royal Australasian College of Surgeons. Rotary clubs and districts continue to be vital partners of Interplast. We extend our heartfelt thanks to each and every Rotarian, Rotary club and district dedicated to repairing bodies and rebuilding lives in the Asia Pacific region.

In acknowledging the significant contribution of Rotarians, we wish to particularly pay tribute to:

- The dedicated Rotarians who volunteer as Interplast District Chair within their area. Together, they have helped connect Interplast to Rotary clubs across Australia and New Zealand, and highlight the importance of essential healthcare across the region
- The nine past District Governors who sit on the Interplast Rotarian Committee, providing strategic and highly valued advice to the Interplast Board and management teams on matters related to Rotary
- The four past District Governors who are Company Members – responsible for electing the Board and holding it accountable
- The two Rotarians who generously give their time and expertise as Directors of the Interplast Board
- The many individual Rotarians who donate to Interplast through their club and district activities.

Every patient who receives treatment from an Interplast volunteer is there because of the initial vision of Rotarians. Every surgeon, anaesthetist, nurse, and allied health professional can offer their time and talent as a direct result of involvement from Rotarians, their clubs, and their districts.

The legacy of Rotary and Rotarians continues to be part of the fabric of Interplast today and into the future.



# HONOURED MEMBERS

The title of Honoured Member is awarded to Interplast supporters who have given exceptional service to Interplast over a period of at least five years and who continue to formally represent Interplast in various activities.

It recognises the accomplishments of distinguished volunteers or supporters to the wider Interplast community and builds a lasting relationship with these valuable individuals. Last year, the Board extended the Honoured Member initiative to include eligibility for our international partners.

**Congratulations to our 2021/22 Honoured Members.**

## Dr Keith Mutimer AM

Few have given as much to Interplast as Dr Keith Mutimer AM. Keith commenced with Interplast in 1984 as a surgeon to the Philippines. Since that initial trip, Keith has undertaken 18 international programs and has left a lasting positive legacy in every location he has served. In recognition of his contribution to international development and surgery, the Sri Lankan College of Plastic Surgeons recognised Keith as an Honorary Fellow.

In addition to his surgical skills, Keith served as a Company Director, Vice President and most recently President, retiring at the Annual General Meeting in 2020. Today, Keith serves Interplast as a Company Member appointed by the Royal Australasian College of Surgeons. Whilst his titles may have differed throughout his involvement, his passion for Interplast's work, and his ongoing advocacy and championing of the organisation makes him a worthy recipient of the title, Honoured Member.

Recently recognised in the Australia Day Honours for his international service, and acknowledged by the Royal Australasian College of Surgeons as the recipient of the RACS International Medal, it is timely and appropriate that Keith Mutimer be acknowledged for his commitment and dedication to the organisation.

---

## Ms Marion Wright

In recognising Marion Wright, the Board wished to acknowledge her contribution to the initial establishment and success of Interplast. Marion was the inaugural General Manager of Interplast for a number of years and amongst the early visionaries to grow the organisation from concept to where we are today.

Marion's initial engagement with Interplast was as a volunteer, where she proved instrumental in the establishment of the organisation. She took Interplast from an emerging NGO to its long-term base at the College of Surgeons.

In her capacity as an initial leader within the organisation, Marion formed some of the lasting overseas and volunteer partnerships still nurtured by Interplast today.

Whilst her role with the organisation has changed, Marion remains a champion of our work, and regularly engages with the CEO and staff team, taking an active role in the strategic objectives and work of Interplast.

All would agree that Marion Wright is a most worthy recipient of the title, Honoured Member.

---



# COMMITTEES AND WORKING GROUPS

During the period of this report, the Company Membership has been constituted as follows:

**Dr Michael McGlynn OAM**  
MBBS FRACS  
Royal Australasian College of Surgeons Nominee

**Dr Keith Mutimer AM**  
MBBS FRACS  
Royal Australasian College of Surgeons Nominee

**Professor David Watters AM**  
OBE  
MB ChB FRCS (Edinburgh)  
FRACS  
Royal Australasian College of Surgeons Nominee

**PDG Marie Dorrington OAM**  
Rotarian Nominee

**PDG Brian Guest**  
Rotarian Nominee

**PDG John Dodd**  
Rotarian Nominee

**PDG John Barnes**  
Rotarian Nominee

**Mr David Inglis AM**  
Bachelor of Arts, Bachelor of Laws  
Independent Nominee

**Professor Mark Ashton MB.**  
BS. MD FRACS  
Australian Society of Plastic Surgeons Nominee

## Board of Directors

**Dr Michael McGlynn OAM**  
Bachelor of Medicine,  
Bachelor of Surgery, Fellow  
Royal Australasian College of Surgeons  
**President**

**Mr Peter Caldwell**  
Diploma of Business Studies (Accounting), Chartered Accountant FCPA  
**Treasurer**

**Ms Marie Dorrington OAM**  
Bachelor of Arts, Diploma of Education, Diploma of Teaching  
**Secretary**

**Mr John Dodd Bachelor of Law and Economics**  
**Director**

**Ms Margaret Jackson AC**  
Bachelor of Economics, Master of Business Administration, Honorary Doctor of Laws, Fellow Institute of Chartered Accountants, Fellow Australian Institute of Company Directors  
**Director**

**Dr Kirstie MacGill**  
Bachelor of Medicine, Bachelor of Surgery, Fellow Royal Australasian College of Surgeons, Diploma in Anatomy, Master of Surgical Education  
**Vice President**

**Ms Amy McLeod**  
Bachelor of Laws, Bachelor of Commerce, Certificate in Governance Practice  
**Director**

**Dr Zachary Moaveni**  
Bachelor of Medicine, Bachelor of Surgery, Fellow Royal Australasian College of Surgeons  
**Director**

**Ms Hayley Morris**  
Bachelor of Arts (Communication)  
**Vice President**

**Dr Philip Ragg**  
Bachelor of Medicine, Bachelor of Surgery, Fellow Australia and New Zealand College of Anaesthetists  
**Director**

**Ms Emma Skinner**  
Bachelor of Pharmacy  
**Director**

**Mr Paul Sundberg**  
Bachelor of Economics (Honours), Chartered Accountant FCA  
**Director**

## Executive Committee

The Committee consisting of the President, Vice Presidents, Secretary and Treasurer meets as required to provide strategic support to the CEO.

## Audit and Risk Committee

The objective of the Audit and Risk Committee is to assist the Board of Directors to discharge its corporate governance responsibilities in relation to financial affairs and compliance with regulatory requirements.

- Mr Paul Sundberg (Chair)
- Mr Peter Caldwell
- Mr Grant Chisnall
- Dr Michael McGlynn
- Ms Amy McLeod
- Mr Frank Micalfeff

## Clinical Governance Committee

The Clinical Governance Committee assists the Board of Directors to discharge its corporate governance responsibilities to exercise due care, diligence and skill in relation to clinical review and risk involved in the implementation of program activities.

- Dr Philip Ragg (Chair)
- Professor Mark Ashton
- Ms Jenny Ball AM
- Mr Chris Bennett
- Ms Gillian Dickinson
- Dr Ian Hogarth
- Mr Damian Ireland
- Mr James Leong
- Associate Professor Michael Leung
- Dr Kirstie MacGill
- Mr Peter Maloney
- Ms Penny McMahon
- Dr David Pescod AO
- Ms Robyn Price
- Mr Anand Ramakrishnan
- Ms Leonie Simmons
- Ms Melissa Woods

## Design, Monitoring & Evaluation Committee

The Design, Monitoring & Evaluation Committee provides programming advice to the Board; ensuring our work meets best practice design & evaluation guidelines.

- Ms Marie Dorrington (Chair)
- Professor David Watters
- Dr David Morgan
- Ms Noreen McGrath
- Dr Michael McGlynn
- Ms Joanne Oxbrow
- Ms Amanda Richmond

## Rotarian Committee

The Rotarian Committee provides professional advice and assistance to the Board of Directors in relation to all matters pertaining to our relationship with Rotary Clubs and Districts across Australia and New Zealand.

- PDG John Dodd (Chair)
- PDG John Barnes
- PDG Gerard Blizzard
- PDG Marie Dorrington
- PDG Linda McLerie
- PDG Ms Di North OAM
- PDG Murray Verso
- PDG Dr Iain Wakefield

## Supporter Engagement Committee

The Supporter Engagement Committee assists the Board of Directors in relation to matters pertaining to fundraising, marketing and communication and supporter engagement strategies.

- Ms Hayley Morris (Chair)
- Mr Gary Ahmad
- Ms Margaret Jackson AC
- Ms Morgan Ryan
- Ms Emma Skinner

## Nurse Working Group

The Nurse Working Group provides clinical and educational advice and assistance to Interplast on the development and evaluation of Interplast nurse education activities.

- Ms Leonie Simmons (Chair)
- Ms Gillian Dickinson
- Ms Angela Doherty
- Mrs Linda Ferguson
- Ms Christine Hunter
- Ms Karolin King
- Ms Hana Menezes
- Ms Jo Oxbrow
- Ms Jan Rice
- Ms Daisy Sargeant
- Ms Annette Tarabaras

## Allied Health Working Group

The Allied Health Working Group provides clinical and educational advice and assistance to Interplast on the development and evaluation of Interplast program activities that include components of hand therapy, physiotherapy and burns rehabilitation.

- Ms Brodwen McBain (Chair)
- Ms Jennifer Ball
- Ms Sharon Goldby
- Ms Katie Anjou
- Mrs Shirley Collocott
- Ms Yvonne Fellner
- Ms Megan Fitzgerald

- Ms Sarah Florisson
- Ms Diana Francis
- Ms Kylie Harrison
- Ms Penny McMahon
- Ms Beth McNeish
- Ms Melissa Parkin

### Interplast Ambassadors

- Ms Turia Pitt
- Mr Mike Rolls
- Ms Jess Hosking

### Interplast Staff

Staff as at 30 June 2022

**Mr Cameron Glover** Chief Executive Officer

**Ms Leanne Abouzeid** Partnerships Advisor

**Ms Alison Chan** Financial Accountant

**Mr Guy Clarke** Head of Program Operations

**Ms Rebecca Dash** Head of Campaigns & Events

**Ms Janette Etherington** Coordinator – Rotary Engagement

**Ms Jess Hill** Director – International Programs (parental leave)

**Mr Peter Huggan** Head of Strategic Projects

**Ms Alice Kent-Brown** Director – Finance & Corporate Services

**Ms Kari Lyon** Coordinator – Workforce Development

**Ms Zoe Martin** Equipment Assistant

**Ms Amanda Richmond** Acting Director – International Programs

**Ms Leonie Simmons** Coordinator – Program Equipment & Resources

**Mr JT Valiente** Coordinator – International Programs

**Ms Amanda Whitty** Head of Corporate Partnerships



# FINANCES

For the year ending 30 June 2022, Interplast recorded a surplus of \$380k. Whilst healthy, this is significantly down on the FY21 result of \$1.34m. In comparing the two years, it is important to note FY21 included a substantial one-off donation of \$1 million. Additionally, JobKeeper payments provided by the Federal Government of \$370k were not repeated in this financial year.

Operating costs totalled \$958k, only slightly higher than FY21 and significantly lower than budget. This was due to delays in recruiting staff at the height of the pandemic, and very tight controls on discretionary spend.

The cost of international programs totalled \$613k, an increase of \$169k compared with FY21.

The balance sheet remains incredibly strong for an organisation the size of Interplast with net assets of \$4.8m+.

**[Interplast's full financial report for FY2022 can be found on the following pages.](#)**



**Interplast**<sup>®</sup>

Repairing bodies & rebuilding lives  
in the Asia Pacific region

**INTERPLAST AUSTRALIA & NEW ZEALAND**

**A.B.N. 59 006 155 193**

**Annual  
Financial Report**

**For the year ended 30 June 2022**



<b>CONTENTS</b>	<b>Page No</b>
Directors' Report.....	1 - 4
Auditor's Declaration of Independence.....	5
Independent Auditor's Report.....	6 - 7
Directors' Declaration.....	8
Statement of comprehensive income.....	9
Statement of financial position.....	10
Statement of changes in equity.....	11
Statement of cash flows.....	12
Notes to the financial statements.....	13 - 21

**Directors’ Report**

The Directors of Interplast Australia & New Zealand (Interplast) submit herewith the annual financial report for the financial year ended 30 June 2022. To comply with the provisions of the *Australian Charities and Not for Profit Act 2012*, the Directors report as follows:

The names of Interplast Directors during, or since the end of the financial year, and the number of meetings each has attended, are set out in the table below.

Directors	Date appointed to current term of office	Date of cessation during the year	2021/22 Board meetings	
			Eligible to attend	Attended
Dr Michael McGlynn OAM (Chair)	November 2019	-	6	6
Mr Peter Caldwell	November 2021	-	6	6
Mr John Dodd	November 2020	-	6	6
Ms Marie Dorrington OAM	November 2021	-	6	6
Ms Margaret Jackson AC	November 2020	-	6	5
Dr Kirstie MacGill	November 2021	-	6	6
Ms Amy McLeod	November 2021	-	6	5
Dr Zachary Moaveni	November 2021		5	5
Ms Hayley Morris	November 2021	-	6	6
Dr Philip Ragg	November 2019	-	6	6
Ms Emma Skinner	November 2020	-	6	6
Mr Paul Sundberg	November 2019	-	6	6

**Principal activities**

The principal activities of Interplast during the financial year were to enable access to life-changing reconstructive surgery and related medical services in developing countries across the Asia Pacific region, through:

- supporting local partners to deliver clinical services;
- building of local medical, nursing and allied health capacity;
- supporting partner hospitals to improve their systems and processes; and
- enabling a number of initiatives to improve the capacity of national health systems.

The use of technology enabled us to continue delivery our strategic objectives remotely as specialist medical teams remained grounded as a direct result of travel restrictions imposed by governments to manage the COVID-19 pandemic.

**Long-term and short-term objectives**

Interplast’s long term objectives are to:

- Improve the quality of life of people with a disability and increase their access to local health systems; and
- Contribute to the development of sustainable health systems and capacity building of health professionals.

Interplast’s short term objectives are to:

- Improve access to treatment for vulnerable and marginalised groups that include people with a disability because of acquired or congenital medical conditions requiring plastic and reconstructive surgery;
- Deliver of safe and effective reconstructive surgery and other medical and allied health services, in partnership with local medical providers; and
- Strengthen local capacity to provide safe and quality reconstructive surgical and related activities to patients through the facilitation of training and professional development.

To achieve these objectives Interplast has adopted the following strategies:

- Attract and retain highly skilled and appropriately qualified volunteers and staff who are committed to Interplast's mission and values;
- Work in partnership with a range of stakeholders, both domestically and internationally to implement activities consistent with local needs and contexts;
- Maintain and enhance relationships with our donors;
- Ensure country program activities are implemented upon the request of partners; and
- Demonstrate accountability and transparency consistent with the Australian Council for International Development's (ACFID) Code of Conduct and Department of Foreign Affairs and Trade (DFAT) requirements.

## Key performance measures

Interplast measures its performance through review of:

- The type and number of activities;
- Number of unique volunteers and number of volunteer hours contributed (reflecting that some individuals engage multiple times per year);
- The number of people reached and receiving treatment at no cost;
- The number of countries and geographical locations reached; and
- The number of local medical, nursing, and allied health professionals receiving training opportunities and the type of training opportunities support.

These benchmarks are used to assess whether Interplast's long and short-term objectives are being achieved.

As with the prior year, the significant health risks, and subsequent global travel restrictions resulting from the COVID-19 pandemic resulted in Interplast not delivering any activities which required the mobilisation of volunteer teams overseas, for the duration of the 2022 financial year.

In FY22, Interplast delivered program activities across 38 countries.

**Information on Directors**

<b>Dr Michael McGlynn</b> <b>OAM</b>	President
Qualifications	Bachelor of Medicine, Bachelor of Surgery, Fellow Royal Australasian College of Surgeons, Harvard Business School
Experience	Elected President 2021
<b>Ms Hayley Morris</b>	Vice-President
Qualifications	Bachelor of Arts (Communications)
Experience	Elected Vice-President 2020
<b>Dr Kirstie MacGill</b>	Vice-President
Qualifications	Bachelor of Medicine, Bachelor of Surgery, Fellow Royal Australasian College of Surgeons, Diploma in Anatomy, Master of Surgical Education
Experience	Elected Vice-President 2021
<b>Mr Peter Caldwell</b>	Treasurer
Qualifications	Diploma of Business Studies (Accounting), Chartered Accountant FCPA
Experience	Elected Treasurer 2020
<b>Ms Marie Dorrington</b> <b>OAM</b>	Secretary
Qualifications	Bachelor of Arts, Diploma of Education, Diploma of Teaching
Experience	Elected Secretary 2020
<b>Mr John Dodd</b>	Director
Qualifications	Bachelor of Law and Economics
<b>Ms Margret Jackson AC</b>	Director
Qualifications	Bachelor of Economics, Master of Business Administration, Honorary Doctor of Laws, Fellow Institute of Chartered Accountants, Fellow Australian Institute of Company Directors
<b>Dr Zachary Moaveni</b>	Director
	Bachelor of Medicine, Bachelor of Surgery, Fellow Royal Australasian College of Surgeons
<b>Ms Amy McLeod</b>	Director
Qualifications	Bachelor of Laws, Bachelor of Commerce, Certificate in Governance Practice
<b>Dr Philip Ragg</b>	Director
Qualifications	Bachelor of Medicine, Bachelor of Surgery, Fellow Australian and New Zealand College of Anaesthetists
<b>Ms Emma Skinner</b>	Director
Qualifications	Bachelor of Pharmacy
<b>Mr Paul Sundberg</b>	Director
Qualifications	Bachelor of Economics (Honours), Chartered Accountant FCA

**Incorporation**

The company is incorporated under the *Corporation Act 2001* and is a company limited by guarantee. If the company is wound up, the constitution states that each member is required to contribute a maximum of \$100 each towards meeting any outstanding obligations of the company. At 30 June 2022, the total amount that members of the company are liable to contribute if the company is wound up \$900 (2021: \$900).

**Review of Operations**

The net operating surplus amounted to \$380,497 (2021: Operating surplus of \$1,338,704).

**Director's Remuneration**

No fees were paid or are payable to the Directors. (2021: \$0).

**Subsequent Events**


There has not been any matter or circumstance, other than that referred to in the Financial Statements or notes thereto, that has arisen since the end of the Financial Year, that has significantly affected, or may significantly affect the operations of the company, the results of those operations, or the state of affairs of the company in future years.

**Auditor's Independence Declaration**

The Auditor's independence declaration is included on page 5.

Signed in accordance with a resolution of the Directors made pursuant to the *Australian Charities and Not for Profit Act 2012*.

On behalf of the Directors



.....  
Michael McGlynn  
Director



.....  
Peter Caldwell  
Director

18 October 2022





Tel: +61 3 9603 1700  
Fax: +61 3 9602 3870  
www.bdo.com.au

Collins Square, Tower Four  
Level 18, 727 Collins Street  
Melbourne VIC 3008  
GPO Box 5099 Melbourne VIC 3001  
Australia

DECLARATION OF INDEPENDENCE BY ELIZABETH BLUNT TO THE DIRECTORS OF INTERPLAST  
AUSTRALIA & NEW ZEALAND

As lead auditor of Interplast Australia & New Zealand for the year ended 30 June 2022, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of section 60-40 of the *Australian Charities and Not-for-profit Commission Act 2012* in relation to the audit; and
2. No contraventions of any applicable code of professional conduct in relation to the audit.

A handwritten signature in black ink, appearing to read 'EB' followed by a stylized flourish.

Elizabeth Blunt  
Director

BDO Audit Pty Ltd  
Melbourne, 18 October 2022

## INDEPENDENT AUDITOR'S REPORT

To the members of Interplast Australia & New Zealand

### Report on the Audit of the Financial Report

#### Opinion

We have audited the financial report of Interplast Australia & New Zealand (the registered entity), which comprises the statement of financial position as at 30 June 2022, the statement of profit or loss and other comprehensive income, the statement of changes in equity and the statement of cash flows for the year then ended, and notes to the financial report, including a summary of significant accounting policies, and the Directors' **declaration**.

In our opinion the accompanying financial report of Interplast Australia & New Zealand, is in accordance with Division 60 of the *Australian Charities and Not-for-profits Commission Act 2012*, including:

- (i) **Giving a true and fair view of the registered entity's financial position** as at 30 June 2022 and of its financial performance for the year then ended; and
- (ii) Complying with Australian Accounting Standards to the extent described in Note 1 and Division 60 of the *Australian Charities and Not-for-profits Commission Regulation 2013*.

#### Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the **Auditor's responsibilities for the audit of the Financial Report** section of our report. We are independent of the registered entity in accordance with the auditor independence requirements of the *Australian Charities and Not-for-profits Commission Act 2012* (ACNC Act) and the ethical requirements of the Accounting Professional and Ethical Standards **Board's APES 110 Code of Ethics for Professional Accountants (including Independence Standards)** (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Emphasis of matter - Basis of accounting

We draw attention to Note 1 to the financial report, which describes the basis of accounting. The financial report has been prepared for the purpose of fulfilling the registered **entity's financial** reporting responsibilities under the ACNC Act. As a result, the financial report may not be suitable for another purpose. Our opinion is not modified in respect of this matter.

#### Other matter

The financial report of Interplast Australia & New Zealand, for the year ended 30 June 2021, was audited by another auditor who expressed an unmodified opinion on that report on 12 October 2021.

#### Other information

The Directors are responsible for the other information. The other information obtained at the date of **this auditor's report is information included in the Directors' Report**, but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information obtained prior to the date of this **auditor's report, we conclude that there is a material misstatement of this other information, we are** required to report that fact. We have nothing to report in this regard.

#### Responsibilities of Directors for the Financial Report

The Directors of the registered entity are responsible for the preparation of the financial report that gives a true and fair view and have determined that the basis of preparation described in Note 1 to the financial report is appropriate to meet the requirements of the ACNC Act. The Directors' **responsibility** also includes such internal control as the Directors determine is necessary to enable the preparation of a financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the Directors **are responsible for assessing the registered entity's** ability to continue as a going concern, disclosing, as applicable, matters relating to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the registered entity or to cease operations, or have no realistic alternative but to do so.

#### **Auditor's responsibilities for the audit of the Financial Report**

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free **from material misstatement, whether due to fraud or error, and to issue an auditor's report that** includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website (<http://www.auasb.gov.au/Home.aspx>) at:

[http://www.auasb.gov.au/auditors\\_responsibilities/ar4.pdf](http://www.auasb.gov.au/auditors_responsibilities/ar4.pdf)

**This description forms part of our auditor's report.**

BDO Audit Pty Ltd



Elizabeth Blunt  
Director

Melbourne, 18 October 2022

## DIRECTORS' DECLARATION


The Directors have determined that the company is not a reporting entity and that this special purpose financial report should be prepared in accordance with the accounting policies described in Note 1 to the financial statements.


The Directors declare that in the Directors opinion:

1. The financial statements and notes, as set out on pages 9 to 21, are in accordance with:
  - a. the *Australian Charities and Not for Profit Commission Act 2012*
  - b. Australian Accounting Standards applicable to the company; and
  - c. give a true and fair view of the financial position of the company as at 30 June 2022 and of the performance for the year ended on that date in accordance with the accounting policies described in Note 1 of the financial statements and
2. There are reasonable grounds to believe that the company is able to pay all of its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors and signed in accordance with subsection 60.15 (2) of the *Australian Charities and Not for Profit Commission regulations 2013*.

On behalf of the Directors

  
.....  
Michael McGlynn  
Director

  
.....  
Peter Caldwell  
Director

18 October 2022

## Statement of Profit or Loss and Other Comprehensive Income

For the year ended 30 June 2022

	Note	2022 \$	2021 \$
<b>REVENUE</b>			
Donations & Gifts - Monetary	15	847,979	1,693,706
Bequests & Legacies		801,942	396,828
Grants			
- Government	16	434,336	763,416
- Other Australian		31,155	48,500
- Overseas		3,986	7,780
Interest		14,900	19,233
Other Income		1,234	1,334
<b>Total revenue</b>		<b>2,135,532</b>	<b>2,930,797</b>
<b>EXPENDITURE</b>			
<i>International aid and development programs expenditure</i>			
<b>International Programs</b>			
- Funds to international programs		612,707	444,111
- Program support costs		246,815	310,036
<b>Community Education</b>		<b>99,215</b>	<b>43,681</b>
<b>Fundraising Costs</b>			
- Public		380,063	276,919
<b>Accountability and Administration</b>		<b>386,378</b>	<b>479,243</b>
<b>Non-Monetary Expenditure</b>		<b>29,857</b>	<b>38,103</b>
<b>Total international aid and development expenditure</b>		<b>1,755,035</b>	<b>1,592,093</b>
Domestic programs		-	-
<b>Total expenditure</b>	4	<b>1,755,035</b>	<b>1,592,093</b>
<b>Excess of revenue over expenditure</b>		<b>380,497</b>	<b>1,338,704</b>
<b>Total comprehensive income</b>		<b>380,497</b>	<b>1,338,704</b>

The accompanying notes form part of these financial statements.



## Statement of financial position

For the year ended 30 June 2022

	Note	2022 \$	2021 \$
<b>ASSETS</b>			
<b>Current assets</b>			
Cash and cash equivalents	3	5,102,988	4,704,916
Listed Investments		59,730	-
Receivables		24,309	9,232
Prepayments		52,846	1,228
Inventories		1,561	502
<b>Total current assets</b>		<b>5,241,434</b>	<b>4,715,878</b>
<b>Non-current assets</b>			
Property and equipment	6	46,419	77,704
<b>Total non-current assets</b>		<b>46,419</b>	<b>77,704</b>
<b>TOTAL ASSETS</b>		<b>5,287,853</b>	<b>4,793,582</b>
<b>LIABILITIES</b>			
<b>Current liabilities</b>			
Payables	7	225,788	95,176
Contract Liabilities	17	127,042	130,339
Provisions	8	118,301	134,174
<b>Total current liabilities</b>		<b>471,131</b>	<b>359,689</b>
<b>Non-current liabilities</b>			
Provisions	8	10,255	7,923
<b>Total non-current liabilities</b>		<b>10,255</b>	<b>7,923</b>
<b>TOTAL LIABILITIES</b>		<b>481,386</b>	<b>367,612</b>
<b>NET ASSETS</b>		<b>4,806,467</b>	<b>4,425,970</b>
<b>EQUITY</b>			
General Reserve	11	1,200,000	1,200,000
Retained Earnings	9	3,606,467	3,225,970
<b>TOTAL EQUITY</b>		<b>4,806,467</b>	<b>4,425,970</b>

The accompanying notes form part of these financial statements.

## Statement of changes in equity

For the year ended 30 June 2022

	\$	\$	\$
	Retained Earnings	General Reserve	Total
<b>Balance at 1 July 2020</b>	<b>1,887,266</b>	<b>1,200,000</b>	<b>3,087,266</b>
Comprehensive income for the year	1,338,704	-	1,338,704
<b>Balance at 30 June 2021</b>	<b>3,225,970</b>	<b>1,200,000</b>	<b>4,425,970</b>
Comprehensive income for the year	380,497	-	380,497
<b>Balance at 30 June 2022</b>	<b>3,606,467</b>	<b>1,200,000</b>	<b>4,806,467</b>

The accompanying notes form part of these financial statements.

## Statement of cash flows

For the year ended 30 June 2022

	Note	2022 \$	2021 \$
<b>Cash flows from operating activities</b>			
Receipts from Government Grants (inclusive of GST)		455,750	522,650
Receipts from Donations, Bequests and Non-Government Grants (inclusive of GST)		1,591,223	2,141,746
Interest received		14,900	19,233
Other income		1,235	1,334
Net GST received		38,685	20,469
Payments to suppliers & employees		(1,703,721)	(1,457,997)
<b>Net cash provided by operating activities</b>		<b>398,072</b>	<b>1,247,435</b>
<b>Cash flows from investing activities</b>			
		-	-
<b>Net cash provided by (used in) financing activities</b>			
		-	-
<b>Net increase in cash held</b>		<b>398,072</b>	<b>1,247,435</b>
Cash at beginning of year		4,704,916	3,457,481
<b>Cash at end of year</b>	3	<b>5,102,988</b>	<b>4,704,916</b>

The accompanying notes form part of these financial statements.

## Notes to the financial statements

### For the year ended 30 June 2022

---

#### 1 Summary of Significant Accounting Policies

The financial statements cover Interplast Australia & New Zealand as an individual entity, incorporated and domiciled in Australia. Interplast Australia & New Zealand is a company limited by guarantee. The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

##### 1.1 Basis of Preparation

In the directors' opinion, the company is not a reporting entity because there are no users dependent on general purpose financial statements.

These are special purpose financial statements that have been prepared for the purposes of complying with the *Australian Charities and Not-for-profits Commission Act 2012* requirements to prepare and distribute financial statements to the members of Interplast Australia & New Zealand. The directors have determined that the accounting policies adopted are appropriate to meet the needs of the members of Interplast Australia & New Zealand.

These financial statements have been prepared in accordance with the recognition and measurement requirements specified by the *Australian Accounting Standards and Interpretations* issued by the Australian Accounting Standards Board ('AASB') and the disclosure requirements of AASB 101 'Presentation of Financial Statements', AASB 107 'Statement of Cash Flows', AASB 108 'Accounting Policies, Changes in Accounting Estimates and Errors', AASB 1048 'Interpretation of Standards' and AASB 1054 'Australian Additional Disclosures', as appropriate for not-for-profit oriented entities.

##### *Historical cost convention*

The financial statements have been prepared under the historical cost convention.

##### *Critical accounting estimates*

The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the company's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 1.2(m).

##### 1.2 New or amended Accounting Standards and Interpretations adopted

The company has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

##### 1.3 Accounting Policies

###### (a) Revenue Recognition

###### *Grants*

To determine if a grant contract should be accounted for under AASB 1058 or AASB 15, Interplast Australia & New Zealand has to determine if the contract is 'enforceable' and contains 'sufficiently specific' performance obligations. When assessing if the performance obligations are 'sufficiently specific', the company has applied significant judgement in this regard by performing a detailed analysis of the terms and conditions contained in the grant contracts, review of

## Notes to the financial statements

### For the year ended 30 June 2022

---

accompanying documentation (e.g. activity work plans) and holding discussions with relevant parties.

#### *Donations and Bequests*

Donations and bequests that are not enforceable or do not contain sufficiently specific performance obligations are accounted for under AASB 1058 and recognised as revenue when received.

#### *Interest*

Interest revenue is recognised as it accrues using the effective interest rate method, which for floating rate financial assets is the rate inherent in the instrument.

#### **(b) Volunteer Services**

Interplast Australia & New Zealand regularly receives volunteer services as part of its operations. Under AASB 1058, private sector not-for-profit entities have a policy option to account for donated services at fair value if the fair value can be reliably measured.

Whilst Interplast Australia & New Zealand has assessed that the fair value of its volunteer services can be reliably measured, it has decided not to adopt the policy option to recognise volunteer services. Accordingly, no amounts are recognised in the financial statements for volunteer services. However, the value of volunteer services has been provided in the notes to the accounts (Refer to Note 18)

#### **(c) Depreciation**

Depreciation is provided on fixed assets and is calculated on a straight-line basis to write off the net cost of each item of Surgical Equipment and Computer & Electrical Equipment over their expected useful lives as follows:

Surgical Equipment	5 - 13 years
Computer & Electrical Equipment	3 - 5 years

#### **(d) Cash and Cash Equivalents**

Cash and cash equivalents include cash on hand, deposits held at-call with banks, other short-term highly liquid investments.

#### **(e) Employee Entitlements**

Provisions made in respect of wages and salaries, annual leave, and other employee entitlements expected to be settled within 12 months, are calculated at salary rates effective at 30 June 2022. Employee benefits payable later than one year have been measured at the present value of the estimated future cash outflows to be made for those benefits. In determining the liability, consideration is given to employee wage increases and the probability that the employee may not satisfy vesting requirements. Those cash outflows are discounted using market yields on corporate bonds with terms to maturity that match the expected timing of cash flows.

Contributions are made by the entity to an employee superannuation fund and are charged as expenses when incurred.

#### **(f) Income Tax**

No provision for income tax has been raised as the entity is exempt from income tax under Division 50 of the *Income Tax Assessment Act 1997*.



## Notes to the financial statements

For the year ended 30 June 2022

---

**(g) Payables**

Payables represent the liability outstanding at the end of the reporting period for goods and services received by the company during the reporting period which remain unpaid. The balance is recognised as a current liability with the amount being normally paid within 30 days of recognition of the liability.

**(h) Goods and Services Tax**

Revenues, expenses and assets are recognised net of the amount of goods and services tax (GST), except:

- a) where the amount of GST incurred is not recoverable from the taxation authority, it is recognised as part of the cost of acquisition of an asset or as part of an item of expense;
- or
- b) for receivables and payables which are recognised inclusive of GST.

The net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables or payables.

Cash flows are included in the statement of cash flows on a gross basis. The GST component of cash flows arising from investing and financing activities which is recoverable from or payable to the taxation authority is classified as operating cash flows.

**(i) Receivables**

Receivables are recorded as amounts due to Interplast Australia & New Zealand at the end of the reporting period.

The company has applied the simplified approach to measuring expected credit losses, which uses a lifetime expected loss allowance. To measure the expected credit losses, trade receivables have been grouped based on days overdue.

**(j) Inventories**

Inventories are measured at the lower of cost or net realisable value.

Inventories acquired at no cost, or for nominal consideration, are valued at the current replacement cost as at the date of acquisition.

**(k) Leases**

The company has a short-term lease over office space at East Melbourne.

As the term of the lease is less than 12 months with no option of rollover, lease payments are recognised as an expense over the lease term.

**(l) Financial Instruments**

Financial assets are classified, at initial recognition, at amortised cost or fair value through profit or loss. When financial assets and liabilities are recognised initially, they are measured at fair value, plus, in the case of instruments not at fair value, through the Statement of Comprehensive Income, directly attributable to transaction costs.

## **Notes to the financial statements**

### **For the year ended 30 June 2022**

---

The classification of financial assets is determined after initial recognition and, when allowed and appropriate, are re-valued at each financial year end. Non-derivative financial liabilities (excluding financial guarantees) are subsequently measured at amortised cost.

#### **(m) Critical Accounting Estimates and Judgements**

The Directors evaluate estimates and judgements incorporated into the financial statements based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the company.

##### **Key estimates**

###### *a) Revenue Recognition*

Key judgements have been made around the recognition of income, as defined in note 1.3(a), as to whether income falls within the scope of AASB 1058 or AASB 15. Some areas of judgement include:

- Assessment of sufficiently specific
- Enforceability of contract

###### *b) Employee benefits provision*

The liability for employee benefits expected to be settled more than 12 months from the reporting date are recognised and measured at the present value of the estimated future cash flows to be made in respect of all employees at the reporting date. In determining the present value of the liability, estimates of attrition rates and pay increases through promotion and inflation have been taken into account.

## **2 Related Party Transactions**

There were no monetary transactions with related parties during the Financial Year. (2021; \$0).

Interplast Australia & New Zealand has obtained professional pro-bono services from members of the Board of Directors. No payment was made for these services.

## Notes to the financial statements

For the year ended 30 June 2022

	2022 \$	2021 \$
<b>3 Notes to the Cash Flow Statement</b>		
<b>Reconciliation of Cash</b>		
Cash at the end of the Financial Year as shown in the cash flow statement is reconciled to the related items in the balance sheet as follows:		
Cash on hand	1,919	919
Cash at bank	5,101,069	4,703,997
	<b>5,102,988</b>	<b>4,704,916</b>
<b>Reconciliation of profit from ordinary activities to net cash flows from operating activities</b>		
Surplus/(Deficit) from ordinary activities	380,497	1,338,704
Non-cash flows in operating surplus		
Depreciation	31,285	52,010
Charges to provisions	(13,541)	56,839
Stock write-off	-	4,565
Listed Investments received through bequest	(59,730)	-
Changes in assets and liabilities, net of the effects of purchase and disposals		
Increase (Decrease) in Deferred Income	(3,297)	(255,503)
Increase (Decrease) in Payables	130,612	22,868
Decrease (Increase) in Receivables	(15,077)	(5,113)
Decrease (Increase) in Prepayments	(51,619)	33,065
Decrease (Increase) in Inventory	(1,058)	-
<b>Cash flows from operations</b>	<b>398,072</b>	<b>1,247,435</b>
<b>4 Expenses</b>		
Total expenditure includes the following specific expenses:		
<i>Depreciation:</i>		
Surgical equipment	29,857	30,923
Computer and electrical equipment	1,428	21,087
	<b>31,285</b>	<b>52,010</b>
<i>Superannuation expense:</i>		
Defined contribution superannuation expense	81,535	70,022

## Notes to the financial statements

For the year ended 30 June 2022

	2022 \$	2021 \$
<b>5 Remuneration of Auditors</b>		
Auditing the Financial Report – BDO	25,000	-
Auditing the Financial Report – William Buck	-	15,000
	<b>25,000</b>	<b>15,000</b>
<b>6 Property Plant and Equipment</b>		
<b>Surgical equipment</b>		
At cost	605,903	607,370
Accumulated depreciation	(561,484)	(533,094)
Net carrying amount	<b>44,419</b>	<b>74,276</b>
<b>Computer and electrical equipment</b>		
At cost	37,254	43,494
Accumulated depreciation	(35,254)	(40,066)
Net carrying amount	<b>2,000</b>	<b>3,428</b>
<b>Total net carrying amount</b>	<b>46,419</b>	<b>77,704</b>
<b>7 Payables</b>		
Payables	164,827	55,224
Accrued Expenses	53,643	37,015
Other Creditors	7,318	2,937
	<b>225,788</b>	<b>95,176</b>
<b>8 Provisions</b>		
<b>(a) Provision for Employee Entitlements</b>		
Annual leave	89,167	64,749
Long service leave	18,571	28,638
Leave in lieu	10,563	1,826
Other	-	38,961
Total Current provisions	<b>118,301</b>	<b>134,174</b>
<b>(b) Non-current</b>		
Long service leave	10,255	7,923
	<b>128,556</b>	<b>142,097</b>

## Notes to the financial statements

For the year ended 30 June 2022

	2022	2021
	\$	\$
<b>9 Retained Earnings</b>		
Balance at beginning of Financial Year	3,225,970	1,887,266
Transfer to General Reserve	-	-
Surplus for year	<u>380,497</u>	<u>1,338,704</u>
Balance at end of Financial Year	<u><u>3,606,467</u></u>	<u><u>3,225,970</u></u>

## 10 Capital and Leasing Commitments

### Lease Commitments

Non-cancellable lease contracted for but not capitalised in the financial statements

Payable – minimum lease payments  
- Less than 12 months

<u>21,435</u>	<u>21,469</u>
<u><u>21,435</u></u>	<u><u>21,469</u></u>

## 11 Reserves

### General Reserve

The general reserve has been established to meet the company's current financial obligations, operating commitments and includes a prudent margin for unforeseen events.

## 12 Contingent Assets and Liabilities

The directors are not aware of the existence of any contingent asset or liability at the end of the reporting period.

## 13 Events after the reporting date

No matter or circumstance has arisen since 30 June 2022 that has significantly affected, or may significantly affect the company's operations, the results of those operations, or the company's state of affairs in future financial years.

## 14 Additional company Information

Interplast Australia and New Zealand is a company limited by Guarantee, incorporated and operating in Australia.

### Principal Place of Business

Royal Australasian College of Surgeons  
250-290 Spring Street  
East Melbourne Vic 3002  
Telephone: (03) 9249 1231

### Principal Registered Office

Minter Ellison Solicitors  
Level 23  
Rialto Towers  
Melbourne Vic 3000



## Notes to the financial statements

For the year ended 30 June 2022

### 15 Restricted Assets

Total "Donations & Gifts – Monetary" includes \$605,183 (2021: \$1,116,434) of donations that are tied to future program expenditure (Restricted Assets). These donations are recognised as income immediately to comply with AASB accounting requirements. Restricted Asset Funds are not available to cover operational expenditure. Total net Restricted Assets at 30 June 2022 was \$2,033,612 (2021: \$1,618,365).

	2022 \$	2021 \$
Restricted Assets Brought Forward	1,618,365	613,235
Donations received on a restricted basis	605,183	1,116,434
Programs funded from Restricted Assets during the year	(189,936)	(111,304)
<b>Closing Balance - Net Restricted Assets</b>	<b>2,033,612</b>	<b>1,618,365</b>

### 16 Government Revenue

Federal Govt – JobKeeper	-	307,650
ATO – Cashflow Boost	-	50,000
State Govt – Jobs Victoria Grant	6,000	-
Department of Foreign Affairs & Trade - ANCP	171,054	405,766
Department of Foreign Affairs & Trade – Programs in The Pacific	257,282	-
<b>Total Government Revenue</b>	<b>434,336</b>	<b>763,416</b>

### 17 Contract Liabilities

Government	41,538	35,110
Non-Government	85,504	95,229
<b>Funding not yet recognised</b>	<b>127,042</b>	<b>130,339</b>

## Notes to the financial statements

For the year ended 30 June 2022

---

### 18 Recognised Development Expenditure: Value of Volunteer Services

The value of volunteer services is not included in the accounts. However, for the purposes of claiming DFAT Recognised Development Expenditure the following information has been prepared in accordance with the rates approved by DFAT.

Australian Volunteers for the year ended 30 June 2022.

	<b>2022</b>	<b>2021</b>
	<b>\$</b>	<b>\$</b>
30 Medical Specialists for a total of 28 days (2021: 38 Medical Specialists for a total of 56 days)	<b>20,658</b>	37,483
24 Allied Health Specialists, Nurse Educators and Nurses for a total of 51 days (2021: 29 Allied Health Specialists, Nurse Educators and Nurses for a total of 30 days)	<b>16,950</b>	12,037
<b>Total Value of Volunteer Services</b>	<b>37,608</b>	49,520

# ACCOUNTABILITY

Interplast operates in a highly regulated environment, with laws, regulations, licenses and codes of conduct that we need to comply with to ensure we remain accountable to the community in our funding countries, and in our program countries.

## In our program countries:

We comply with all the regulations and expectations of each country in which we work. We ensure that all medical volunteers have relevant medical registrations, along with the correct visas. We also comply with all Customs requirements regarding medical equipment and supplies. We abide by all local laws and protocols, along with following the work practices of our partner hospitals. We only go where we have been invited and have the approval of local authorities.

## Australian Charities and Not for Profit Commission

As a registered charity, Interplast is required to comply with the Australian Charities and Not for Profit Commission (ACNC) Act 2012. This includes complying with Australian Accounting standards and other mandatory professional reporting requirements.

## Australian Taxation Office

The Australian Taxation Office has given Interplast the status of a Deductible Gift Recipient, granted exemption from Income Tax and provided concession for Fringe Benefits Tax and GST. Reporting requirements comprise mainly annual fringe benefits tax returns, quarterly Business Activity Statements and monthly pay-as-you-go (PAYG) submissions.

## DFAT Accreditation

Interplast is accredited by the Australian Government Department of Foreign Affairs and Trade (DFAT), which is responsible for managing the Australian Government's aid program. To

maintain accreditation, Interplast's systems, policies and processes are rigorously reviewed by the Australian Government every five years. Accreditation ensures the transparent and accountable use of funding, and covers our entire portfolio, including non-development activities and activities that are not funded by DFAT.

As an accredited agency and trusted recipient of funds, Interplast receives support from DFAT through the Australians NGO Cooperation Program (ANCP).

## ACFID

Interplast is a member of the Australian Council for International Development (ACFID) and a signatory to the ACFID Code of Conduct. ACFID is the peak body for aid and international development NGOs and its code of conduct upholds the highest standards of ethics, effectiveness and accountability. For further information about the Code, please refer to the ACFID Code of Conduct Guidance Document available at [acfid.asn.au](http://acfid.asn.au).

Complaints relating to a breach of the ACFID Code of Conduct by an ACFID member can be made to the ACFID Code of Conduct Committee ([www.acfid.asn.au/code-of-conduct/complaints](http://www.acfid.asn.au/code-of-conduct/complaints)).

## Fundraising

Fundraising licenses are required by all states in Australia in order to raise funds within their borders.

Interplast holds all required licenses and complies with the requirements associated with these licenses, which include such conditions as providing extra reporting to particular states.

Interplast is a member of the Fundraising Institute of Australia (FIA) and complies with the FIA Code of Conduct.

## Complaints

Interplast has a process for handling any complaints. The complaints policy and process can be found on our website at [interplast.org.au](http://interplast.org.au). If you wish to lodge a complaint about Interplast, send an email to [contactus@interplast.org.au](mailto:contactus@interplast.org.au), phone our office on 03 9249 1231 or mail the office listed on the back cover of this report.



# CHANGE FUTURES, TOGETHER

Achieving Interplast's vision of providing access to life-changing surgical and related healthcare for all, can only be achieved with the support of the many incredible individuals, groups and businesses who join us in raising funds and promoting the work of our organisation.

**Please support us to ensure our life-changing work can continue.**

**[INTERPLAST.ORG.AU/DONATE](https://www.interplast.org.au/donate)**



**Interplast**<sup>®</sup>

Interplast Australia & New Zealand

Royal Australasian College of Surgeons Building  
250 - 290 Spring Street  
East Melbourne VIC 3002

T +61 3 9249 1231

[contactus@interplast.org.au](mailto:contactus@interplast.org.au)  
[www.interplast.org.au](http://www.interplast.org.au)